Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Star Media Group of Malaysia to use Cxense DMP and personalization software

Oslo, Norway – 25 September 2018 – Cxense ASA (OSE: CXENSE) today announced that Star Media Group Bhd (MYX: 6084), one of the largest media companies in Malaysia, has signed an agreement to use Cxense's Data Management Platform (DMP) with Intelligent Personalization.Star Media Group holds a leading position in Malaysia as an integrated and innovative media company and has developed progressively from a single-product publisher to a multichannel media group with a strong presence in print, digital, radio, TV and events. Founded in 1971, it is the home of The Star, a member of the Asia News

Promising research results from a Multi-Frequency Vibrometry study will be presented at the European Association for the Study of Diabetes in Berlin

The senior specialist at Skåne University Hospital, Dr. Eero Lindholm, will present study results showing that it may be possible to reverse nerve damage in feet caused by diabetes by improved metabolic control. VibroSense Dynamics participates as an exhibitor at EASD in Hall 4 at booth 4J05.Dr. Lindholm's poster presentation shows very promising results which indicate that impairment of the nerve function of the feet caused by diabetes may be reversible by means of improved metabolic control. Improved metabolic control means in this respect that patients that lowers their long-term

Article about MGMT study accepted for publication in Neoplasma

A scientific article on Double Bond Pharmaceutical's investigation into how MGMT status affects the effectiveness of treatment with Temodex has been accepted for publication in the journal Neoplasma."The information from the survey provides important understanding into the therapeutic value of Temodex, and we are pleased to publish our findings about Temodex and MGMT in a high-quality scientific journal. Thanks to close cooperation with all involved parties we have been able to accomplish this very quickly. ", - says Igor Lokot, CEO of Double Bond Pharmaceutical. "This survey confirms

Mekonomen's Nomination Committee

In accordance with the resolution of the Annual General Meeting on 9 May 2018, Mekonomen has established a Nomination Committee. This Committee shall prepare and submit proposals to the Annual General Meeting to be held on 10 May 2019 regarding: · the election of a Chairman of the Annual General Meeting, · the number of Board members and deputies, · the election of the Chairman of the Board and other Board members, · Board fees and any remuneration for committee work, · the election of and fees for auditors, and · guidelines for appointment of the Nomination Committee

Extraordinary general meeting in Capio AB (publ)

The shareholders of Capio AB are hereby invited to attend the Extraordinary General Meeting (the “Meeting”) for the primary purpose of resolving on an approval of the proposed sale of Capio Santé SA. The Meeting will be held at Mannheimer Swartling Advokatbyrå, Östra Hamngatan 16, 403 14 Gothenburg, at 4:00 p.m. CEST on Thursday 18 October 2018. Registration will commence from 3:30 p.m. CEST.A. RIGHT TO PARTICIPATE IN THE EXTRAORDINARY GENERAL MEETING Shareholders who wish to participate in the Meeting must: firstly, be registered in the share register maintained by Euroclear Sweden

Bactiguard now available in Sweden’s second largest county

In October last year, Bactiguard won a tender for urinary catheters for Sweden’s second largest county, the Västra Götaland region (VGR), but the tender was appealed in other areas than Bactiguard's products. Now the contract is in place, and healthcare providers in both primary and secondary care and 49 municipalities in the region can purchase Bactiguard's urinary catheters for infection prevention.”We are very pleased that the contract is finally in place so that our activities can get started in Sweden's second largest region. With this contract, our urinary catheters will be available

Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN)

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that post-hoc results from its clinical Phase 2b study NEFIGAN will be presented in an oral session at the International IgA Nephropathy Network meeting (IIgANN) in Buenos Aires, Argentina, on Friday September 28, 2018.The oral presentation of the abstract – with the title Treatment of IgA nephropathy with Nefecon, a targeted‑release formulation of budesonide – extended posthoc results from the Nefigan trial – will be presented by Prof. Bengt Fellström, MD, PhD, from the Department of Medical Sciences, Uppsala University,

Capio announces notice of Extraordinary General Meeting and information on the use of proceeds from the proposed sale of Capio France

Capio today announces the notice of the Extraordinary General Meeting (the “EGM”) convened to resolve on the Board’s proposal to approve the sale of Capio France. The EGM will be held at 4.00 p.m. CEST on 18 October 2018. Capio also announces information on the use of proceeds from the sale of Capio France, should the EGM approve the transaction.The proceeds from the transaction will be used partly to pay down Capio Group debt and partly as a return of cash to shareholders. The return of cash to shareholders is expected to be between BSEK 1.8-2.1, equating to SEK 13-15 on a current per

NEW INITIATIVES FOR SMART MEDTECH

Technology company Semcon is increasing its focus on Life Science. Smart technical solutions can be used to improve care and welfare for patients and healthcare staff alike. A new framework agreement has also been concluded with AstraZeneca, applicable to everything from product and production development to product information.“We have extensive experience of Life Science, developing digital solutions that add a great deal of value in the field of healthcare, for instance. We have seen good results from our previous partnership with AstraZeneca, and we are pleased that they have chosen to

Finnair receives Five-Star Global Airline rating from APEX based on customer reviews

Finnair has been awarded a 2019 Five Star Global Airline rating by the Airline Passenger Experience Association (APEX). The airline ratings are based entirely on verified feedback given by passengers. Only 9% of airlines worldwide received sufficient votes for the prestigious five-star status in 2019. Finnair was one of 470 passenger rated airlines through 31 July of this year. Airline travelers were validated against confirmed itineraries and geo-location on mobile devices. This is the first time Finnair receives a five-star rating from the APEX organization. “We are proud and

Resurs Bank makes management changes: recruits new CIO and appoints new COO

Sebastian Green has been recruited as the new CIO of Resurs Bank. His most recent position was as CIO of Bergendahls Food and he will take up his new duties at Resurs in the autumn of 2018. “With his experience of pursuing strategic IT development in the retail industry at a Nordic level, Sebastian’s expertise will play an important role in Resurs’s mission to offer innovative and relationship-building payment solutions and services. Sebastian will add important expertise to our Group Management and I look forward to welcoming him to the company,” says Kenneth Nilsson, CEO. Another

Resurs Bank makes management changes: recruits new CIO and appoints new COO

Sebastian Green has been recruited as the new CIO of Resurs Bank. His most recent position was as CIO of Bergendahls Food and he will take up his new duties at Resurs in the autumn of 2018. “With his experience of pursuing strategic IT development in the retail industry at a Nordic level, Sebastian’s expertise will play an important role in Resurs’s mission to offer innovative and relationship-building payment solutions and services. Sebastian will add important expertise to our Group Management and I look forward to welcoming him to the company,” says Kenneth Nilsson, CEO. Another

Susanne Lithander taking office as CFO of NCC on November 12

Susanne Lithander will take office as CFO of NCC on November 12 and join NCC’s Executive Management Team. She comes from BillerudKorsnäs, where she worked as CFO for seven years. “I welcome Susanne Lithander to NCC. She has a great deal of solid experience from similar roles that will serve us well in the important restructuring work we are now carrying out,” said Tomas Carlsson, President and CEO of NCC. Susanne, born in 1961, is presently CFO at BillerudKorsnäs. She was previously CEO of Mercuri International and worked in several roles at Ericsson. “I am very much looking

Read original

Swedish Issue Price

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.    THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL

Terveystalo Plc: Juha Tuominen, Chief Medical Officer of Terveystalo leaves the company

Terveystalo Plc Stock Exchange release 25 September 2018 at 9:00 a.m. EEST Juha Tuominen (Professor, MD, Ph.D), Chief Medical Officer of Terveystalo since 2009, has been elected as the new Managing Director of Hospital District of Helsinki and Uusimaa, starting from 1 January 2019. Terveystalo has started the search for the successor of Mr. Tuominen. Unto Palonen, senior physician of occupational healthcare will act as a deputy Chief Medical Officer of Terveystalo from 1 November 2018 onwards.  "I would like to thank my supervisor, Mr. Yrjö Närhinen and my fellow colleagues for the

Metsä Tissue Mänttä mill switches to LNG in tissue paper production

The LNG company Skangas and Metsä Tissue Corporation have entered into an agreement on the supply of liquefied natural gas (LNG) to the Mänttä tissue paper mill for production process use. At the mill in Mänttä, Finland, LNG will replace liquefied petroleum gas (LPG) in the paper drying process. The fuel switch from LPG to LNG will improve competitiveness and cut the company’s carbon dioxide emissions.LNG will be delivered to the Mänttä mill by road tanker from the Skangas Pori LNG terminal. Before being used, LNG will be regasified at the mill. In cooperation with the Technical Services of

Polygiene grows organization in North America with appointment of new Commercial Director, Bobby Howell

As Commercial Director of North America, Bobby Howell, based in Vancouver, will cover the West Coast region. He will work together with Hans Bergman, also Commercial Director North America, based in Montreal, and responsible for the eastern half of North America. Howell has valuable experience and a great network in the sport and outdoor industry as he joins with past work experience at premium brands, Arc'teryx, Assos and 7Mesh. His background in both sales and marketing as well as digital strategy will be of great value for the Company. ”Polygiene has established partnerships

Precision cancer therapy with Elekta Unity now available in the UK at The Royal Marsden and The Institute of Cancer Research, London

LONDON, September 25, 2018 – Elekta (EKTA-B.ST) today announced that The Royal Marsden and The Institute of Cancer Research (ICR), London, have clinically implemented Elekta Unity, a transformative magnetic resonance radiation therapy (MR/RT) system that ushers radiotherapy into the age of personalized, precision medicine. Elekta Unity is the first system to combine high-field (1.5 Tesla) MR imaging, precision radiation therapy and intelligent software, and is capable of MR/RT, a personalized precision cancer therapy. Elekta Unity received its CE mark in June 2018, and is being clinically

Magnolia Bostad issues new four-year unsecured bonds of SEK 500 million

Magnolia Bostad has successfully issued unsecured bonds in an amount of SEK 500 million under a framework of up to SEK 700 million.The new bonds are due in October 2022 and carries a floating interest rate of STIBOR 3m + 8.50 per cent. Magnolia Bostad intends to list the new bonds on the corporate bond list at Nasdaq Stockholm.The proceeds from the bond issue will be used to finance Magnolia Bostad's continued expansion, refinancing of existing debt (including bonds) and new acquisitions. Nordea Bank AB (publ) has acted as financial advisor for the bond issue.  For further information,

Placing of senior secured bonds in Eniro with a total nominal value of approximately SEK 989 million

This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus. For further information, please refer to “Important information” in this press release.

Risk factors of Alzheimer’s disease and metabolic syndrome can accumulate already in childhood

Genetic predisposition to Alzheimer's disease is linked to an increased risk of cardiometabolic disorders already in childhood, a new study from Finland shows. Ongoing at the University of Eastern Finland, the findings from the Physical Activity and Nutrition in Children Study, PANIC, were published in the Journal of Alzheimer’s Disease. Alzheimer's disease is the most common memory disorder. In addition to genetic predisposition, the risk of Alzheimer’s disease is also increased by cardiometabolic risk factors, such as type 2 diabetes. The accumulation of these risk factors is known as

KONE hosts a Capital Markets Day today, on September 25, 2018, in Helsinki

KONE Corporation, press release, September 25, 2018 at 07.00 a.m. EEST KONE hosts a Capital Markets Day today, on September 25, 2018, in Helsinki KONE organizes a Capital Markets Day for institutional investors and analysts in Helsinki today, on September 25, 2018. The aim of the Capital Markets Day is to provide an update on KONE's progress in its strategy execution and the key focus areas going forward. Both strategic and financial targets remain unchanged. President and CEO Henrik Ehrnrooth: "We are making good progress towards our strategic targets with our Winning with

Mekonomen announces the terms of its rights issue

Mekonomen AB (publ) (”Mekonomen” or the ”Company”) announced on 24 August 2018 that the Board of Directors had resolved, subject to approval at the extraordinary general meeting on 26 September 2018, to launch a rights issue with preferential rights for existing shareholders. Mekonomen’s Board of Directors today announces the terms of the rights issue through this press release. The rights issue in brief: · Shareholders in Mekonomen have preferential rights to subscribe for four (4) new shares per seven (7) existing shares, indicating a subscription ratio of 4:7. · The

Asarina Pharma: sharp rise on first day of trading on Nasdaq First North

After 40 years’ of research developing its breakthrough PMDD treatment Sepranolone, Asarina Pharma hit the ground running on Monday 24 September as it launched on Nasdaq First North in Stockholm. With major institutions getting behind the research—how did the successful market launch feel for the scientific and business team at Asarina Pharma?WHAT DOES TODAY MEAN TO YOU? CEO, Peter Nordkild: “We’ve come a long way–yet in many ways this is just another beginning. Now it’s time to deliver. A successful flotation increases our responsibility to deliver the results from our Phase IIB study

There are no items matching the current filter
There are no more items matching the current filter
Back to top